Phase 2 ADHD Trial, Recruiting NCT05133804 Sponsor: University of Haifa Condition: ADHD
Back to Adhd

Phase 2 ADHD Trial, Recruiting

NCT05133804
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with PTSD (post-traumatic stress disorder) based on recognised medical guidelines
  • You are currently receiving care at the outpatient clinic at Lev HaSharon Netanya Adult Clinic
  • You are between 20 and 60 years old
  • You received your PTSD diagnosis at least one month before joining the study
  • You are not currently being re-exposed to the traumatic event that caused your PTSD
  • If you take any psychiatric medications, you have been on a stable, unchanged dose for at least one month before the study begins

Who may not be able to join:

  • You have another major mental health condition, such as psychosis, depression, bipolar disorder, or borderline personality disorder, or you are currently having thoughts of suicide
  • You have been diagnosed with ADHD
  • You have a significant ongoing physical illness that limits your daily activities, such as an autoimmune disease, AIDS, or kidney failure
  • You have a heart or cardiovascular condition, such as high blood pressure, irregular heart rhythm, or a slow heart rate
  • You have a serious, life-threatening illness such as a recent heart attack, breathing failure, or cancer
  • You have a neurological condition affecting your nervous system, such as multiple sclerosis, Alzheimer's disease, Parkinson's disease, epilepsy, or a history of stroke
  • You have had a severe brain injury in the past or currently
  • You have glaucoma (a condition affecting eye pressure)
  • You have significant hearing loss or impairment
  • You are currently pregnant or breastfeeding
  • You are currently dependent on substances, including regular use of medical cannabis
  • You have used steroid medications within the two months before the study starts
  • You are taking medications that may affect how your brain and nervous system work (confirm with trial site)
  • You are unable or unwilling to complete all parts of the research process

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Avi Avital, PhD, University of Haifa

Phone: +972-4-8420-364

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
University of Haifa
Registry
ClinicalTrials.gov
Start date
1 June 2022
Est. completion
1 July 2025

Where this trial is recruiting

🇮🇱 Israel

Primary endpoints

Change in Clinician-Administered Posttraumatic Stress Disorder Scale for the Diagnostic and Statistical Manual (DSM)-5 (CAPS-5) between baseline score (before treatment) and score on day 26 (after treatment)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov